Epilepsy Research
Volume 30, Issue 2 , Pages 153-158 , April 1998

The anticonvulsant zonisamide scavenges free radicals

Received 18 September 1997 ,Revised 24 November 1997 ,Accepted 25 November 1997.

References 

  1. Akaike K, Yoshida M, Miyamoto Y, Sato K, Kohno M, Sasamoto K, et al. Antagonistic action of imidazolineoxyl N-oxidase agonist endothelium-derived reluxing factor/·NO through a radical reaction. Biochemistry. 1993;32:827–832
  2. Dowson VL, Dawson TM. Pathological roles of nitric dioxide in the central nervous system. In:  Packer L,  Hiramatsu M,  Yoshikawa T editor. Free Radicals in Brain Physiology and Disorders. San Diego: Academic Press; 1996;p. 83–100
  3. Endo A. Effect of zonisamide on neurotransmitter release from hippocampal slice of El mice: A study of neurotransmitter release using an improved experimental system. Okayama Igaku Zasshi. 1995;107:69–78in Japanese
  4. Ferrendelli JA, Blank AC, Gross RA. Relationships between seizure activity and cyclic nucleotide levels in brain. Brain Res. 1980;200:93–103
  5. Halliwell B, Gutterridge JMC. Free Radicals in Biology and Medicine. 2nd ed. Oxford: Clarendon Press; 1989;
  6. Hamada K, Ishida S, Yagi K, Seino M. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats. Neurosciences. 1990;16:407–412
  7. Hammond EJ, Perchalski RJ, Wilder BJ. Neurophamacology of zonisamide, A new antiepileptic drug. Gen. Pharmacol. 1987;18:303–307
  8. Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia. 1986;27:367–374
  9. Ito T, Hori M, Masuda Y, Yoshida K, Shimizu M. 3-Sulfamoylmethyl-1,2-benzeisoxazole: a new type of anticonvulsant drug. Electroencephalographic profile. Arzneim-Forsch. Drug Res. 1987;30:603–609
  10. Janzen EG. Spin trapping. In:  Packer L editors. Methods in Enzymology. 105:Orlando, Florida; 1986;p. 188–198
  11. Kitani K, Sato Y, Kanai S, Nokubo M, Ohta M, Masuda Y. Increasing anticonvulsant effects of AD-810 (zonisamide) in aging BDF1 mice. Life Sci. 1987;41:1339–1344
  12. Kito M, Maehara M, Watanabe K. Antiepileptic drugs–calcium current interaction in cultured human neuroblastoma cells. Seizure. 1994;3:141–149
  13. Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences. 1995;21:23–29
  14. Manzoni O, Prezeau U, Marin P, Deshager S, Bockaert J, Fagni L. Nitric oxide-induced blockade of NMDA receptors. Neuron. 1992;8:654–662
  15. Matsumoto K, Miyazaki H, Fujii I, Kagemoto A, Maeda T, Hashimoto M. Adsorption, distribution and excretion of 3-(sulfamoyl[14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and AD-810 in man. Arzneim-Forsch. Drug Res. 1983;33:961–968
  16. Mimaki T, Tanoue H, Matsunaga Y, Miyazaki H, Mino M. Regional distribution of 14C-zonisamide in rat brain. Epilepsy Res. 1994;17:233–236
  17. Mori A. Reactive oxygen species and mechanism of induction of seizure by guanidino compound. In:  Packer L,  Hiramatsu M,  Yoshikawa T editor. Free Radical in Brain Physiology and Disorders. 15:San Diego: Academic Press; 1996;p. 3–15
  18. Narahashi N, Tsunoo A, Yoshii M. Characterization of two types of calcium channels in mouse neuroblastoma cells. J. Physiol. 1987;383:231–249
  19. Noda Y, Anzai K, Mori A, Kohno M, Shimmei M, Packer L. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem. Mol. Biol. Int. 1997;42:35–44
  20. Okada M, Kaneko S, Hirano T, Ishida M, Kondo T, Otani K, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res. 1992;13:113–119
  21. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193–205
  22. Rosen GM, Rauckman EJ. Spin trapping of superoxide and hydroxyl radicals. In:  Packer L editors. Methods in Enzymology. 105:Orlando, Florida: Academic Press; 1984;p. 198–209
  23. Sackellares JC, Donofrio PD, Wargner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia. 1985;26:206–211
  24. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185–188
  25. Seino M, Miyazaki H, Ito T. Zonisamide. In:  Pisani F,  Perucca E,  Avanzini G,  Richens A editor. New Antiepileptic Drugs, Epilepsy Research. Amsterdam: Elsevier; 1991;p. 169–174
  26. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 1992;12:21–27
  27. Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives, 1. Chem. Pharm. Bull. 1976;24:632–643
  28. Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivates. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem. 1979;22:180–191
  29. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia. 1985;26:212–220

PII: S0920-1211(97)00097-1

Epilepsy Research
Volume 30, Issue 2 , Pages 153-158 , April 1998

Article Tools

* Image Usage & Resolution